ATE170744T1 - Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe - Google Patents

Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe

Info

Publication number
ATE170744T1
ATE170744T1 AT96940616T AT96940616T ATE170744T1 AT E170744 T1 ATE170744 T1 AT E170744T1 AT 96940616 T AT96940616 T AT 96940616T AT 96940616 T AT96940616 T AT 96940616T AT E170744 T1 ATE170744 T1 AT E170744T1
Authority
AT
Austria
Prior art keywords
active ingredients
controlled release
poorly soluble
medicinal products
basic
Prior art date
Application number
AT96940616T
Other languages
English (en)
Inventor
Neville W Board
Alan F Carmody
Liam C Feely
Brian C Withers
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170744(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE170744T1 publication Critical patent/ATE170744T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
AT96940616T 1995-12-19 1996-11-25 Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe ATE170744T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/574,877 US5705190A (en) 1995-12-19 1995-12-19 Controlled release formulation for poorly soluble basic drugs

Publications (1)

Publication Number Publication Date
ATE170744T1 true ATE170744T1 (de) 1998-09-15

Family

ID=24298013

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96940616T ATE170744T1 (de) 1995-12-19 1996-11-25 Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe
AT0065504U AT7918U1 (de) 1995-12-19 2004-09-03 Feste orale pharmazeutische zusammensetzung mit kontrollierter freisetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0065504U AT7918U1 (de) 1995-12-19 2004-09-03 Feste orale pharmazeutische zusammensetzung mit kontrollierter freisetzung

Country Status (27)

Country Link
US (1) US5705190A (de)
EP (1) EP0799028B1 (de)
JP (1) JP3292732B2 (de)
KR (1) KR100632187B1 (de)
CN (1) CN1131027C (de)
AR (1) AR004391A1 (de)
AT (2) ATE170744T1 (de)
AU (1) AU701268B2 (de)
CA (1) CA2209714C (de)
CZ (1) CZ289158B6 (de)
DE (2) DE69600620T2 (de)
DK (1) DK0799028T3 (de)
ES (1) ES2122810T3 (de)
HK (1) HK1016873A1 (de)
HU (1) HUP9800516A3 (de)
IL (1) IL121275A (de)
IT (1) ITMI20050383U1 (de)
NZ (1) NZ323332A (de)
PL (1) PL186696B1 (de)
PT (1) PT103379B (de)
RO (1) RO117501B1 (de)
RU (1) RU2142793C1 (de)
TR (1) TR199800777T2 (de)
TW (1) TW429154B (de)
UA (1) UA40663C2 (de)
WO (1) WO1997022335A1 (de)
ZA (1) ZA9610110B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SK282427B6 (sk) * 1997-06-11 2002-01-07 Abbott Laboratories Pevná farmaceutická kompozícia s riadeným uvoľňovaním
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
TR200002771T2 (tr) * 1998-03-26 2001-02-21 Fujisawa Pharmaceutical Co.,Ltd. Devamlı salımı olan preparatlar
NZ509832A (en) * 1998-08-21 2003-11-28 Novartis Ag New oral formulation for 5-HT4 agonists or antagonists
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
IL151496A0 (en) * 2000-02-29 2003-04-10 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
IN192748B (de) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
HUP0500791A2 (en) * 2001-08-29 2006-09-28 Ranbaxy Lab Ltd Controlled release formulation of clarithromycin or tinidazol
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
US7037523B2 (en) * 2001-11-02 2006-05-02 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
EP1592453A1 (de) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate aufbau von milnacipran für orale einnahme
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004100880A2 (en) * 2003-05-06 2004-11-25 Nirmal Mulye Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP2529730A1 (de) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Orale Zusammensetzung mit verlängerter Freisetzung
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
WO2005030257A2 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
CN100435847C (zh) * 2004-05-13 2008-11-26 宝龄富锦生技股份有限公司 含有难溶解性主药之持续释放配方
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
CN1322866C (zh) * 2004-10-12 2007-06-27 广州贝氏药业有限公司 一种多单元缓释制剂
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
ES2531215T3 (es) * 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
EP1976492B8 (de) * 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Wirkstofffreisetzungssysteme mit leicht basischen wirkstoffen und organischen säuren
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (de) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
SI2234607T1 (sl) * 2007-12-28 2011-11-30 Acraf Formulacija s počasnim sproščanjem na osnovi asociacije glikogena in alginata
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
US8900680B2 (en) * 2009-05-29 2014-12-02 Tetra Laval Holdings & Finanace S.A. Packaging material comprising magnetisable portions
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
JP5628910B2 (ja) * 2009-07-07 2014-11-19 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５ｈ−ピロロ［３，４−ｂ］ピラジンの配合物
EP2283824B1 (de) 2009-07-30 2017-04-19 Special Products Line S.p.A. Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
WO2011026234A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
CN102106807B (zh) 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
ES2753198T5 (es) 2010-12-16 2023-05-31 Amgen Europe Gmbh Formas farmacéuticas orales de liberación controlada de fármacos poco solubles y sus usos
DE102013202703B4 (de) 2013-02-20 2020-03-12 Siemens Healthcare Gmbh Vorrichtung und Verfahren zur Kollisionserkennung bei einem medizintechnischen Gerät
KR20230145545A (ko) 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
WO2017027778A1 (en) 2015-08-13 2017-02-16 Temple University-Of The Commonwealth System Of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018207188A1 (en) * 2017-05-11 2018-11-15 Steadymed, Ltd. Enhanced solubility drug-containing formulations
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN111184699A (zh) * 2020-04-09 2020-05-22 河北大学 一种硝苯地平控释胶囊及其制备方法
US20230203477A1 (en) 2020-05-26 2023-06-29 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296140A (en) * 1977-03-08 1981-10-20 Tri/Valley Growers Molded gelled pimiento body
GB1566609A (en) * 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
EP0188040B1 (de) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Feste Zubereitung mit langsamer Freisetzung
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
IL121275A0 (en) 1998-01-04
AT7918U1 (de) 2005-11-15
EP0799028B1 (de) 1998-09-09
PT103379B (pt) 2007-02-28
CZ289158B6 (cs) 2001-11-14
DK0799028T3 (da) 1999-06-07
TR199800777T2 (xx) 1998-07-21
CN1131027C (zh) 2003-12-17
NZ323332A (en) 1998-04-27
ZA9610110B (en) 1997-06-18
AR004391A1 (es) 1998-11-04
RO117501B1 (ro) 2002-04-30
DE29624506U1 (de) 2004-12-09
WO1997022335A1 (en) 1997-06-26
AU1025297A (en) 1997-07-14
TW429154B (en) 2001-04-11
RU2142793C1 (ru) 1999-12-20
HUP9800516A2 (hu) 1998-08-28
JP3292732B2 (ja) 2002-06-17
CZ221297A3 (en) 1997-12-17
MX9706031A (es) 1997-11-29
JPH11513406A (ja) 1999-11-16
PL186696B1 (pl) 2004-02-27
EP0799028A1 (de) 1997-10-08
CA2209714A1 (en) 1997-06-26
CA2209714C (en) 2002-07-30
KR100632187B1 (ko) 2008-09-24
HK1016873A1 (en) 1999-11-12
PL321363A1 (en) 1997-12-08
HUP9800516A3 (en) 2000-07-28
IL121275A (en) 2003-10-31
ITMI20050383U1 (it) 2006-06-20
UA40663C2 (uk) 2001-08-15
DE69600620D1 (de) 1998-10-15
ES2122810T3 (es) 1998-12-16
AU701268B2 (en) 1999-01-21
DE69600620T2 (de) 1999-05-06
CN1205629A (zh) 1999-01-20
KR19980701832A (ko) 1998-06-25
US5705190A (en) 1998-01-06

Similar Documents

Publication Publication Date Title
ATE170744T1 (de) Arzneimittel mit gesteuerter wirkstofffreisetzung für basische schwerlösliche wirkstoffe
NO20021111D0 (no) Anvendelse av 5-O-deoaminyl-6-O-metylerytronolid A-derivater for fremstilling av biologisk aktive produkter
ATE201989T1 (de) Arzneimittel mit kontrollierter wirkstoffabgabe
AU7547196A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU5945396A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
DE69723303D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe
DE69528769T2 (de) Aerosolformulierung für arzneimittel enthaltend polyglycolisierte glyzeride
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE69534283D1 (de) Clonidinhaltiges arzneimittel mit verzögerter wirkstoffabgabe
EE9800109A (et) 5-O-desosaminüül-6-O-metüülerütronoliid A uued derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete produktide valmistamiseks
FI972949A (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
AU6828996A (en) Products and processes for the sustained release of agricultural active ingredients
ATE210976T1 (de) Arzneimittel bestehend aus diclofenac
BR9607169A (pt) Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
BR9600217A (pt) 4-aminobenzoilguanidinas processo para a preparação de seus derivados processo para a produção de formulações farmacêuticas formulação farmacêutica e uso
DE69622648D1 (de) Benzoxalepin-derivate, deren salze und diese enthaltende arzneimittel
EE03658B1 (et) Pestitsiidpreparaadid ja protsess nende valmistamiseks
FI960740A0 (fi) Substituoituja bentseenisulfonyyliureoita ja -tioureoita, menetelmä niiden valmistamiseksi, niiden käyttö farmaseuttisten valmisteiden valmistukseen ja niitä sisältäviä lääkkeitä
AU8079891A (en) Bile alcohol and drug containing the same as active ingredient
FR2735694B1 (fr) Le cladinose a titre de medicament et les compositions pharmaceutiques les renfermant
IT1277123B1 (it) Formulazioni farmaceutiche per il rilascio controllato e costante di principi attivi costituite da matrici idrofile parzialmente rivestite
BR9504987A (pt) Filme para conservação de produtos agrícolas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked